Navigation Links
MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
Date:1/10/2012

KENNESAW, Ga., Jan. 10, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has received the certification for the Company's proprietary CollaFix™ Surgical Mesh CD.  This certification of CollaFix™ Surgical Mesh CD, which is a Class III product in Europe, was issued by the Company's notified body, AMTAC Certification Services, Limited, based in the United Kingdom.

This certification is the first for the Company's CollaFix™ platform technology.

Parker H. "Pete" Petit, Chairman and CEO commented, "We are very pleased to receive our first regulatory certification for our unique CollaFix™ technology.  Our collagen fibers, that are the size of human hair, are fabricated in continuous lengths and have similar strength and stiffness to human tendons.  The fibers are bio-compatible and resorbable.  We expect this certification to be the first of many in a line of products using our CollaFix™ technologies to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair."

CollaFix™ Surgical Mesh CD has not been cleared for use in the United States.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix®, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane,
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
6. MiMedx Announces Launch of AmnioFix™
7. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
8. MiMedx Group Announces 2010 Results
9. MiMedx Group Announces First Quarter 2011 Results
10. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, ... of an agreement with Novella Clinical (Novella), ... in patients with newly diagnosed glioblastoma. Novella is a ... services to small to mid-sized oncology companies. The ICT-107 ... in the US, Europe and ...
(Date:7/3/2015)... ... ... global failure analysis market is expected to reach $7,147.0 million by 2020, at a ... at the highest CAGR of 8.46%; its growth is expected to be driven by ... for root cause analysis of failure. The market based on the geographic regions has ...
(Date:7/2/2015)... , ... July 03, 2015 , ... Cuvettes have been used in countless labs for ... to find the cuvette they needed. As expected, this was a daunting and tiring ... wrong part because they were not able to navigate the complex catalog structure. , Now ...
(Date:7/2/2015)... ... 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... today the acquisition of Turner Medical, Inc ., thus becoming a global ... the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... efforts of two kinds of bacteria to produce hydrogen in ... the other. According to an article in the August issue ... bonus: leftover enzymes can be used to scavenge precious metals ... convert hydrogen into energy. , Hydrogen has three times more ...
... 6, 2008 TIME: 9:30 ... Dr. Candace Kendle, Chairman and CEO, Kendle (Nasdaq: KNDL ... Aug. 6 at 9:30 a.m. Eastern Time to,discuss its financial results ... session will follow., Webcast Instructions, To access the live ...
... (Nasdaq: SGMO ) today announced that the company ... July 23,2008, after the market closes. The press release ... PT, which will be open to the public via,telephone ... review,the financial results and discuss other business matters., ...
Cached Biology Technology:Fuel from food waste: bacteria provide power 2Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 3
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... 2013 -- A test that measures the expression levels ... effectively differentiate between patients who are at higher and ... the body more than five years after diagnosis, researchers ... individual risk prediction for women with these cancers is ...
... have been bombarded by stories in the media and on ... levels, and urging high doses of supplements to protect against ... But new research from Johns Hopkins finds that blood ... of the range suggested by the Institute of Medicine confer ...
... experimental drug has shown promise in treating influenza, preventing lung ... to University of Maryland School of Medicine researchers publishing in ... found that a drug called Eritoran can protect mice from ... of influenza virus. The potential value of this drug as ...
Cached Biology News:Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 2Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 3Vitamin D: More may not be better 2University of Maryland School of Medicine researchers find potential novel treatment for influenza 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
...
Biology Products: